As global pharmaceutical companies continue to expand into emerging markets, they must address a range of issues – varied demographics, the sourcing and quality of data, shifting payer requirements, and increased scrutiny of business practices. In the Fall 2013 issue of the Health Care Consulting Services Bulletin, we focus on opportunities, risks, and challenges that companies in international health care are confronting.
Press attention has been trained on government investigations of pharmaceutical firms’ marketing practices in China, India, Eastern Europe, and elsewhere. Managing Principal Paul Greenberg describes how economists can play an important role in these cases.
When a new renal cell carcinoma treatment faced global reimbursement challenges – because an available on-market drug was considered “standard of care” – Analysis Group undertook an international epidemiological study of patients receiving the existing therapy.
Analysis Group researchers used data from Québec, Canada’s provincial health plan to assess the prevalence of combining or switching ADHD therapies, as well as to evaluate the impact of generic substitution on epilepsy patients.
Across international pharmaceutical markets, the criteria used to assess the value of new therapies in relation to standards of care vary markedly and are changing rapidly. Read about how manufacturers can determine national and regional payer responses to new therapies, and hear from Vice President Christian Frois on how market access and pricing decisions can drive success in emerging markets.
Governments seeking to contain public spending on drugs often set reimbursement based on benchmark countries. Read about how this practice – called reference pricing – can impact global market dynamics.
Managing Principal Paul Greenberg discussed reverse payment patent settlements in “Little Guidance For Lower Courts In FTC v. Actavis” (Today’s General Counsel, August/September 2013). Consultant Justin Works and Managing Principal Andrew Parece demonstrated potential shortcomings in traditional pricing approaches in “On-Market Pricing Strategies: How to Optimize ROI without Hitting the Cliff” (Pharmaceutical Executive, June 2013).
Analysis Group Health Care consultants have recently given presentations and won awards at several conferences around the globe, including ISPOR, AAIC, and ICPE.
Analysis Group-Beijing provides health care research and strategic consulting to multinational pharmaceutical and life sciences clients in the world’s third-largest pharmaceutical market.
Led by Managing Principal Eric Qiong Wu, the office identifies and develops high-quality data with local partners and collaborates with leading academics.
Health Care Bulletin: Fall 2013